Interestingly, the simultaneous activation of Kras and Nrf2 by Kras mutation and Keap1 deletion, respectively, did not promote pancreatic cancer development but led to pancreatic atrophy [73]. This evidence concerns the gene NFE2L2 and familial pancreatic carcinoma.